Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

DepoVax™ is an innovative and strongly immunogenic vaccine platform. Survivin is highly expressed in many tumor types and has reported prognostic value. To generate tumor-specific immune response, a novel cancer vaccine was formulated in DepoVax platform (DPX-Survivac) using survivin HLA class I pep...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Berinstein, Neil L, Karkada, Mohan, Oza, Amit M, Odunsi, Kunle, Villella, Jeannine A, Nemunaitis, John J, Morse, Michael A, Pejovic, Tanja, Bentley, James, Buyse, Marc, Nigam, Rita, Weir, Genevieve M, MacDonald, Lisa D, Quinton, Tara, Rajagopalan, Rajkannan, Sharp, Kendall, Penwell, Andrea, Sammatur, Leeladhar, Burzykowski, Tomasz, Stanford, Marianne M, Mansour, Marc
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
MIATA Compliant Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4570133/
https://ncbi.nlm.nih.gov/pubmed/26405584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1026529
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados